title: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.
authors.affiliation: Department of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA. defurst@mednet.ucla.edu
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Furst
authors.forename: Edward Clark
authors.initials: EC
authors.lastname: Keystone
authors.forename: Alexander K
authors.initials: AK
authors.lastname: So
authors.forename: Jürgen
authors.initials: J
authors.lastname: Braun
authors.forename: Ferry C
authors.initials: FC
authors.lastname: Breedveld
authors.forename: Gerd R
authors.initials: GR
authors.lastname: Burmester
authors.forename: Fabrizio
authors.initials: F
authors.lastname: De Benedetti
authors.forename: Thomas
authors.initials: T
authors.lastname: Dörner
authors.forename: Paul
authors.initials: P
authors.lastname: Emery
authors.forename: Roy
authors.initials: R
authors.lastname: Fleischmann
authors.forename: Allan
authors.initials: A
authors.lastname: Gibofsky
authors.forename: J R
authors.initials: JR
authors.lastname: Kalden
authors.forename: Arthur
authors.initials: A
authors.lastname: Kavanaugh
authors.forename: Bruce
authors.initials: B
authors.lastname: Kirkham
authors.forename: Philip
authors.initials: P
authors.lastname: Mease
authors.forename: A
authors.initials: A
authors.lastname: Rubbert-Roth
authors.forename: Joachim
authors.initials: J
authors.lastname: Sieper
authors.forename: Nora G
authors.initials: NG
authors.lastname: Singer
authors.forename: Josef S
authors.initials: JS
authors.lastname: Smolen
authors.forename: Piet L C M
authors.initials: PL
authors.lastname: Van Riel
authors.forename: Michael H
authors.initials: MH
authors.lastname: Weisman
authors.forename: Kevin L
authors.initials: KL
authors.lastname: Winthrop
mesh_terms: D000069594:Abatacept; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D012216:Rheumatic Diseases / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014503:Urate Oxidase / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; C511911:belimumab; D000069594:Abatacept; D014503:Urate Oxidase; C502936:tocilizumab; C031545:Pegloticase